Diabetes Care, Vol 20, Issue 6 925-928, Copyright © 1997 by American Diabetes Association

ARTICLES

Contraindications to metformin therapy in patients with NIDDM

TV Sulkin, D Bosman and AJ Krentz
Diabetes Resource Centre, Royal South Hants Hospital, Southampton, U.K.

OBJECTIVE: Treatment with metformin is occasionally associated with the development of severe lactic acidosis. However, this is usually observed in patients with major contraindications to the drug. In this study, we aimed to determine the prevalence of conditions currently regarded as either contraindications or cautions to the use of metformin in patients with NIDDM. RESEARCH DESIGN AND METHODS: The case notes of metformin-treated NIDDM patients (mean age 62 years) attending a United Kingdom university hospital diabetes clinic over a 3-month period were reviewed according to criteria reflecting a pragmatic view of current prescribing recommendations. RESULTS: Of 89 consecutive patients whose notes could be evaluated in detail, only 41 (46%) had no contraindications or cautions to metformin whatsoever. Concomitant chronic disorders associated with a potentially increased risk of hyperlactatemia were renal impairment (n = 2; plasma creatinine concentrations 1.7 and 2.3 mg/dl, respectively), cardiac failure (n = 2), and chronic liver disease (n = 2). Other potentially relevant disorders included ischemic heart disease (n = 20), clinical proteinuria (n = 14), peripheral vascular disease (n = 22), and pulmonary disease (n = 7). Multiple conditions (i.e., two, three, or four) were present in eight, five, and one patient(s), respectively. CONCLUSIONS: More than half the patients in our series had concomitant conditions or complications conventionally regarded as cautions or contraindications to metformin; approximately 10% had a multiplicity of such conditions. Regular surveillance is necessary to detect the development of complications such as renal impairment. Vigilance is also required in view of the increased risk of major intercurrent illnesses, which may independently disturb lactate metabolism in patients with NIDDM. Metformin should be withdrawn promptly under such circumstances.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A A Tahrani, G I Varughese, J H Scarpello, and F W F Hanna Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? BMJ, September 8, 2007; 335(7618): 508 - 512. [Full Text] [PDF]

				H. M. Sharabash, T. L. Remington, P. Mar, R. Winston, P. C. Walker, and T. Pollmacher Changes in weight and glucose tolerance during treatment with mirtazapine. Diabetes Care, January 1, 2006; 29(1): 170 - 170. [Full Text] [PDF]

				S. E. Inzucchi Metformin and Heart Failure: Innocent until proven guilty Diabetes Care, October 1, 2005; 28(10): 2585 - 2587. [Full Text] [PDF]

				J. McCormack, K. Johns, and H. Tildesley Metformin's contraindications should be contraindicated Can. Med. Assoc. J., August 30, 2005; 173(5): 502 - 504. [Full Text] [PDF]

				L. Kennedy, W. H. Herman, and for the GOAL A1C Study Team Renal Status Among Patients Using Metformin in a Primary Care Setting Diabetes Care, April 1, 2005; 28(4): 922 - 924. [Full Text] [PDF]

				R. I. Misbin The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes Diabetes Care, July 1, 2004; 27(7): 1791 - 1793. [Full Text] [PDF]

				P English and G Williams Hyperglycaemic crises and lactic acidosis in diabetes mellitus Postgrad. Med. J., May 1, 2004; 80(943): 253 - 261. [Abstract] [Full Text] [PDF]

				S. Clement, S. S. Braithwaite, M. F. Magee, A. Ahmann, E. P. Smith, R. G. Schafer, and I. B. Hirsch Management of Diabetes and Hyperglycemia in Hospitals Diabetes Care, February 1, 2004; 27(2): 553 - 591. [Full Text] [PDF]

				S. R. Salpeter, E. Greyber, G. A. Pasternak, and E. E. Salpeter Risk of Fatal and Nonfatal Lactic Acidosis With Metformin Use in Type 2 Diabetes Mellitus: Systematic Review and Meta-analysis Arch Intern Med, November 24, 2003; 163(21): 2594 - 2602. [Abstract] [Full Text] [PDF]

				D. Dawson and C. Conlon Case Study: Metformin-Associated Lactic Acidosis: Could orlistat be relevant? Diabetes Care, August 1, 2003; 26(8): 2471 - 2472. [Full Text] [PDF]

				G C Jones, J P Macklin, and W D Alexander Contraindications to the use of metformin BMJ, January 4, 2003; 326(7379): 4 - 5. [Full Text] [PDF]

				J. K Khan, M. Pallaki, S. R Tolbert, and T. R Hornick Lactic Acidemia Associated with Metformin Ann. Pharmacother., January 1, 2003; 37(1): 66 - 69. [Abstract] [Full Text] [PDF]

				C. Horlen, R. Malone, B. Bryant, B. Dennis, T. Carey, M. Pignone, and R. Rothman Frequency of Inappropriate Metformin Prescriptions JAMA, May 15, 2002; 287(19): 2504 - 2505. [Full Text] [PDF]

				A. T. Calabrese, K. C. Coley, S. V. DaPos, D. Swanson, and R. H. Rao Evaluation of Prescribing Practices: Risk of Lactic Acidosis With Metformin Therapy Arch Intern Med, February 25, 2002; 162(4): 434 - 437. [Abstract] [Full Text] [PDF]

				J. H. Scarpello Review: Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes The British Journal of Diabetes & Vascular Disease, January 1, 2001; 1(1): 28 - 36. [Abstract] [PDF]

				A. J Krentz, C. J Bailey, and A. Melander Thiazolidinediones for type 2 diabetes BMJ, July 29, 2000; 321(7256): 252 - 253. [Full Text]